<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387266</url>
  </required_header>
  <id_info>
    <org_study_id>NPC004</org_study_id>
    <nct_id>NCT04387266</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC</brief_title>
  <official_title>A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective real-world study to evaluate the efficacy and feasibility of modified
      reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local failure-free survival (LFFS)</measure>
    <time_frame>60 month</time_frame>
    <description>The duration of time to LFFS was calculated from the date of histological diagnosis until documented treatment local failure.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Modified reduce-volume target IMRT</arm_group_label>
    <description>Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>modified reduce-volume target IMRT</intervention_name>
    <description>The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.</description>
    <arm_group_label>Modified reduce-volume target IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-metastatic NPC patients treated with modified reduce-volume target IMRT in our
        institution
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was
             nasopharyngeal carcinoma;

          2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT;

          3. Patients with baseline MRI date of nasopharynx and neck, and completed the first
             course of treatment in our hospital;

          4. Diagnosis time: November 1, 2014 to December 31 , 2017

        Exclusion Criteria:

          1. Disease progression during IMRT;

          2. Previous malignancy or other concomitant malignant diseases;

          3. The evaluation information of tumor efficacy can not be obtained;

          4. Receive blind treatment in other clinical research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaojun Lin, DR</last_name>
    <phone>13860603879</phone>
    <email>linshaojun@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiaojuan Guo, DR</last_name>
    <phone>15080013157</phone>
    <email>guoqiaojuan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of radiation oncology, Fujian cancer hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

